Search research articles
Contact Us
Filters
Showing results (111-120 of 390) with videos related to
Page
of 39
Sort By:
CNS Drugs
|
September 30, 2018
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
Alexander Klistorner, Yi Chai, Letizia Leocani, et al.
Plos One
|
November 13, 2012
Altered topological organization of white matter structural networks in patients with neuromyelitis optica
Yaou Liu, Yunyun Duan, Yong He, et al.
Journal of Neuropathology and Experimental Neurology
|
May 2, 2003
Schwann cell apoptosis in the postnatal axotomized sciatic nerve is mediated via NGF through the low-affinity neurotrophin receptor
Steven Petratos, Helmut Butzkueven, Kylie Shipham, et al.
Plos One
|
May 29, 2015
Parallel changes in structural and functional measures of optic nerve myelination after optic neuritis
Anneke van der Walt, Scott Kolbe, Peter Mitchell, et al.
Neuroimage
|
January 24, 2009
Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis
Scott Kolbe, Caron Chapman, Thanh Nguyen, et al.
Therapeutic Advances in Neurological Disorders
|
October 4, 2021
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
Helmut Butzkueven, Ludwig Kappos, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
April 3, 2020
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 16, 2025
Choroid Plexus Enlargement in Secondary Progressive MS: phenotype comparison
Samuel Klistorner, Michael H Barnett, Chenyu Wang, et al.
Brain Sciences
|
February 25, 2022
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study
Helmut Butzkueven, Paul S Giacomini, Stanley Cohan, et al.
Multiple Sclerosis and Related Disorders
|
November 14, 2025
Choroid plexus enlargement in secondary progressive MS: phenotype comparison
Samuel Klistorner, Michael H Barnett, Chenyu Wang, et al.
Page
of 39
Search research articles
Search
Showing results (111-120 of 390) with videos related to
Sort By:
Page
of 39
CNS Drugs
|
September 30, 2018
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
Alexander Klistorner, Yi Chai, Letizia Leocani, et al.
Plos One
|
November 13, 2012
Altered topological organization of white matter structural networks in patients with neuromyelitis optica
Yaou Liu, Yunyun Duan, Yong He, et al.
Journal of Neuropathology and Experimental Neurology
|
May 2, 2003
Schwann cell apoptosis in the postnatal axotomized sciatic nerve is mediated via NGF through the low-affinity neurotrophin receptor
Steven Petratos, Helmut Butzkueven, Kylie Shipham, et al.
Plos One
|
May 29, 2015
Parallel changes in structural and functional measures of optic nerve myelination after optic neuritis
Anneke van der Walt, Scott Kolbe, Peter Mitchell, et al.
Neuroimage
|
January 24, 2009
Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis
Scott Kolbe, Caron Chapman, Thanh Nguyen, et al.
Therapeutic Advances in Neurological Disorders
|
October 4, 2021
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
Helmut Butzkueven, Ludwig Kappos, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
April 3, 2020
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 16, 2025
Choroid Plexus Enlargement in Secondary Progressive MS: phenotype comparison
Samuel Klistorner, Michael H Barnett, Chenyu Wang, et al.
Brain Sciences
|
February 25, 2022
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study
Helmut Butzkueven, Paul S Giacomini, Stanley Cohan, et al.
Multiple Sclerosis and Related Disorders
|
November 14, 2025
Choroid plexus enlargement in secondary progressive MS: phenotype comparison
Samuel Klistorner, Michael H Barnett, Chenyu Wang, et al.
Page
of 39